References
- Przepiorka D, Ko CW, Deisseroth A, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21:4035–4039.
- Food and Drug Administration (FDA) [Internet]. Blinatumomab full prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf
- Amgen Canada, Inc [Internet]. Blinatumomab product monograph. Available from: https://www.amgen.ca/products/∼/media/EF8EA4314B6E4E1593F187023DB8F129.ashx
- Health Canada [Internet]. BLINCYTO (blinatumomab) – risk of pancreatitis. Healthy Canadians; [cited 2016 Jul 13]. Available from: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59308a-eng.php
- Amgen, Inc [Internet]. Blinatumomab full prescribing information. Available from: http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdf
- European Medicines Agency [Internet]. Blinatumomab summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003731/WC500198228.pdf
- Amgen, Inc. Australia [Internet]. Blinatumomab product information. Available from: http://www.guildlink.com.au/gc/ws/amgen/pi.cfm?product=anpblinp11115
- Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847.
- FDA Adverse Event Reporting System (FAERS) [Internet]. FAERS database. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
- European Medicines Agency (EMA) [Internet]. EudraVigilance European database of suspected drug reaction reports. Available from: http://www.adrreports.eu/en/index.html
- McKoy JM, Fisher MJ, Courtney DM, et al. Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 2013;36:335–347.
- Hospira Inc, Clinical Information Technology Division [Internet]. Theradoc. Available from: http://www.theradoc.com
- Starren JB, Winter AQ, Lloyd-Jones DM. Enabling a learning health system through a unified enterprise data warehouse: the experience of the Northwestern University Clinical and Translational Sciences (NUCATS) Institute. Clin Transl Sci. 2015;8:269–271.
- Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10:796–803.
- Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidem Drug Safe. 2001;10:483–486.